One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers
Luke J. Laffin, MD, a Dennis Bruemmer, MD, a Michelle Garcia, RN, b Danielle M. Brennan, MS, b Ellen McErlean, MSN,b Douglas S. Jacoby, MD, c Erin D. Michos, MD,d Paul M Ridker, MD, e Tracy Y. Wang, MD, f Karol E. Watson, MD,g Howard G. Hutchinson, MD,h Steven E. Nissen, MD
doi : 10.1016/j.jacc.2022.10.013
Volume 81, Issue 1, 3–10 January 2023, Pages 1-12
Supplements are commonly used by individuals with indications for lipid-lowering therapy, but evidence of their effectiveness to lower low-density lipoprotein cholesterol (LDL-C) is lacking, particularly when compared with statins.
Caution Against Rejecting All Dietary Supplements for LDL Cholesterol Reduction∗
Kevin C. Maki, PHD, a,b Mary R. Dicklin, PH D
doi : 10.1016/j.jacc.2022.11.004
Volume 81, Issue 1, 3–10 January 2023, Pages 13-15
Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes: Meta-Analysis of Randomized Trials
Candrika D. Khairani, MD, MMS C, a, * Antoine Bejjani, MD,a, * Gregory Piazza, MD, MS,a,b David Jimenez, MD, P HD, c Manuel Monreal, MD, PH D, d Saurav Chatterjee, MD, e Vittorio Pengo, MD,f Scott C. Woller, MD,g,h Josefina Cortes-Hernandez, MD, PH D, i Jean M. Connors, MD,j Yogendra Kanthi, MD, k,l Harlan M. Krumholz, MD, SM, m,n,o Saskia Middeldorp, MD, PH D, p Anna Falanga, MD,q,r Mary Cushman, MD, MS C,s,t Samuel Z. Goldhaber, MD, a,b David A. Garcia, MD,u Behnood Bikdeli, MD, MS
doi : 10.1016/j.jacc.2022.10.008
Volume 81, Issue 1, 3–10 January 2023, Pages 16-30
The efficacy and safety of direct oral anticoagulants (DOACs) for patients with thrombotic antiphospholipid syndrome remain controversial.
Warfarin Is the Preferred Therapy for Patients With Thrombotic APS: Back to the Future∗
Mark A. Crowther, MD, a Aubrey E. Jones, P HARMD, MSCI, b Daniel M. Witt, PHARMD, BCPS b
doi : 10.1016/j.jacc.2022.10.015
Volume 81, Issue 1, 3–10 January 2023, Pages 31-33
Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
Martin S. Maron, MD,a Ahmad Masri, MD, b Lubna Choudhury, MD, c Iacopo Olivotto, MD, d Sara Saberi, MD,e Andrew Wang, MD, f Pablo Garcia-Pavia, MD, P HD, g,h Neal K. Lakdawala, MD,i Sherif F. Nagueh, MD, j Florian Rader, MD, k Albree Tower-Rader, MD, l Aslan T. Turer, MD,m Caroline Coats, MD, PHD, n Michael A. Fifer, MD,l Anjali Owens, MD,o Scott D. Solomon, MD,i Hugh Watkins, MD, PH D, p Roberto Barriales-Villa, MD,q Christopher M. Kramer, MD, r Timothy C. Wong, MD, s Sharon L. Paige, MD, PH D, t Stephen B. Heitner, MD, t Stuart Kupfer, MD,t Fady I. Malik, MD, PHD, t Lisa Meng, P HD, t Amy Wohltman, ME, t Theodore Abraham, MD,u on behalf of the REDWOOD-HCM Steering Committee and Investigators
doi : 10.1016/j.jacc.2022.10.020
Volume 81, Issue 1, 3–10 January 2023, Pages 34-45
Left ventricular outflow tract (LVOT) obstruction is a major determinant of heart failure symptoms in obstructive hypertrophic cardiomyopathy (oHCM). Aficamten, a next-in-class cardiac myosin inhibitor, may lower gradients and improve symptoms in these patients.
Myosin Inhibitors: The Next Generation∗
Ajith Nair, MD, a Lola Xie, MD, a Jorge E. Silva Enciso, MD
doi : 10.1016/j.jacc.2022.10.018
Volume 81, Issue 1, 3–10 January 2023, Pages 46-48
Outcomes of Percutaneous Intervention in Patients With Takayasu Arteritis
George Joseph, DM, a Viji S. Thomson, DM, a Thomas V. Attumalil, DM, a Pratheesh G. Mathen, DM, a Arpudh M. Anandaraj, DM,a Oommen K. George, DM, a Paul V. George, DM, a Ruchika Goel, DM, b Sathish Kumar, MD, c John Mathew, DM,b Debashish Danda, DM
doi : 10.1016/j.jacc.2022.10.024
Volume 81, Issue 1, 3–10 January 2023, Pages 49-64
The status of vascular lesion treatment using percutaneous intervention (PI) in Takayasu arteritis (TAK) remains unresolved.
Percutaneous Intervention in Takayasu Arteritis: Potential Advantages of Procedural Perseverance∗
Neeraj Dhaun, MBC HB, PHD, a Dan Pugh, MBC HB, a Taryn Youngstein, MB BS, MD
doi : 10.1016/j.jacc.2022.11.009
Volume 81, Issue 1, 3–10 January 2023, Pages 65-67
Tropical Cardiovascular Diseases: The Forgotten Orphans
Raman Krishna Kumar, MD DM FAHA, a,b,c Valentin Fuster, MD, P HD, d,e Dorairaj Prabhakaran, MD, DM, FNA, DSC
doi : 10.1016/j.jacc.2022.11.003
Volume 81, Issue 1, 3–10 January 2023, Pages 68-70
Infections and Cardiovascular Disease: JACC Focus Seminar 1/4
Juan M. Farina, MD, a Kiera Liblik, MS C,b Pablo Iomini, MD,c Andrés F. Miranda-Arboleda, MD, b,d,e Clara Saldarriaga, MD, f Ivan Mendoza, MD,g Ezequiel J. Zaidel, MD, h José M. Rubio-Campal, MD, i Alvaro Sosa-Liprandi, MD, h Adrian Baranchuk, MD
doi : 10.1016/j.jacc.2022.08.813
Volume 81, Issue 1, 3–10 January 2023, Pages 71-80
The burden of cardiovascular diseases is sharply rising in low- and middle-income countries (LMICs).
Rheumatic Heart Disease: JACC Focus Seminar 2/4
Scott Dougherty, MBC HB, a Emmy Okello, MBC HB, MMED , P HD, b Jeremiah Mwangi, MA, c Raman Krishna Kumar, MD, DM
doi : 10.1016/j.jacc.2022.09.050
Volume 81, Issue 1, 3–10 January 2023, Pages 81-94
It is a sad reality that although eminently preventable, and despite possessing such knowledge for >70 years, rheumatic heart disease (RHD) remains the most common cause of cardiovascular morbidity and early mortality in young people worldwide.
Paradigm Shift: Children Present the Most Critical Point of Engagement for Choosing Cardiovascular Health
Valentin Fuster, MD, P HD, Editor-in-Chief, Journal of the American College of Cardiology
doi : 10.1016/j.jacc.2022.11.020
Volume 81, Issue 1, 3–10 January 2023, Pages 95-96
“Trust Me. I’m a Doctor�
Edward T.A. Fry, MD, FACC,
doi : 10.1016/j.jacc.2022.11.021
Volume 81, Issue 1, 3–10 January 2023, Pages 97-99
Genetic Cardiomyopathy Masquerading as Cardiac Sarcoidosis
Mallika Lal, MD Chris Chen, MD Brittaney Newsome, PA-C Luke Masha, MD, MPH Samuel A. Camacho, MD Ahmad Masri, MD, MS *Babak Nazer, MD
doi : 10.1016/j.jacc.2022.10.021
Volume 81, Issue 1, 3–10 January 2023, Pages 100-102
